Literature DB >> 23727416

Characterization of ciprofloxacin resistant Escherichia coli isolates among men undergoing evaluation for transrectal ultrasound guided prostate biopsy.

Chao Qi1, Michael Malczynski, Anthony J Schaeffer, Grace Barajas, Robert B Nadler, Marc H Scheetz, Teresa R Zembower.   

Abstract

PURPOSE: We determine the prevalence of ciprofloxacin resistant gram-negative bacilli in patients scheduled for transrectal ultrasound guided prostate biopsy, characterize the Escherichia coli strains recovered from this patient population, and characterize the mechanisms responsible for β-lactam and ciprofloxacin resistance.
MATERIALS AND METHODS: Rectal swabs from 991 patients were cultured for ciprofloxacin resistant gram-negative bacilli with a selective medium. Recovered E. coli isolates were further analyzed with susceptibility testing, pulsed field gel electrophoresis, plasmid isolation and sequencing.
RESULTS: A total of 193 ciprofloxacin resistant gram-negative bacilli were recovered and of these isolates 167 (87%) were E. coli. The prevalence of ciprofloxacin resistant E. coli in the study population was 17%. Only 38 (26%) of the 149 E. coli isolates that received susceptibility testing were susceptible to ampicillin and ampicillin-sulbactam. In select isolates transferrable plasmids carrying β-lactamase were responsible for the resistance to the β-lactam agents and other nonβ-lactam antimicrobials. Diverse combinations of gyrA and parC mutations associated with fluoroquinolone resistance were identified. Strain typing and plasmid typing indicated that the E. coli isolates did not share a common origin.
CONCLUSIONS: Of the patients in our study 17% carried ciprofloxacin resistant E. coli. Analysis of resistance mechanisms and plasmid analysis along with strain typing demonstrated that this patient population harbored organisms with heterogeneous phenotypic susceptibility, indicating that universal prophylaxis would not provide optimal coverage for patients undergoing transrectal ultrasound guided prostate biopsy.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CLSI; Clinical and Laboratory Standards Institute; ESBL; FQ; MAC; MIC; MacConkey; PFGE; QRDR; SXT; TRUSP; biopsy; drug resistance; extended spectrum β-lactamase; fluoroquinolone; fluoroquinolones; infection; microbial; minimal inhibitory concentration; prostate; pulsed field gel electrophoresis; quinolone resistance-determining region; transrectal ultrasound guided prostate biopsy; trimethoprim-sulfamethoxazole

Mesh:

Substances:

Year:  2013        PMID: 23727416     DOI: 10.1016/j.juro.2013.05.059

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  An antimicrobial prophylaxis protocol using rectal swab cultures for transrectal prostate biopsy.

Authors:  Stephen J Summers; Darshan P Patel; Blake D Hamilton; Angela P Presson; Mark A Fisher; William T Lowrance; Andrew W Southwick
Journal:  World J Urol       Date:  2015-05-03       Impact factor: 4.226

2.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years.

Authors:  Liam Toner; Nathan Papa; Sani H Aliyu; Harveer Dev; Nathan Lawrentschuk; Samih Al-Hayek
Journal:  World J Urol       Date:  2015-10-28       Impact factor: 4.226

Review 3.  Reducing infection rates after prostate biopsy.

Authors:  Florian M E Wagenlehner; Adrian Pilatz; Przemyslaw Waliszewski; Wolfgang Weidner; Truls E Bjerklund Johansen
Journal:  Nat Rev Urol       Date:  2014-01-14       Impact factor: 14.432

4.  [Prostate cancer detection rates: comparison of standard biopsy with prompt rebiopsy and a one-time extended biopsy].

Authors:  Z Türk; H Hollberg; T Dill; I Kaspers; H Isbarn
Journal:  Urologe A       Date:  2015-01       Impact factor: 0.639

5.  Bacterial Urinary Tract Infection after Transrectal Placement of Fiducial Markers prior to Proton Radiotherapy for Prostate Cancer.

Authors:  William M Mendenhall; Gabriella Glassman; Christopher G Morris; Joseph A Costa; Christopher R Williams; Stephanie E Harris; Stephen E Mandia; Bradford S Hoppe; Randal H Henderson; Curtis M Bryant; R Charles Nichols; Nancy P Mendenhall
Journal:  Int J Part Ther       Date:  2016-08-29

Review 6.  Prevention of sepsis prior to prostate biopsy.

Authors:  Liam Toner; Damien M Bolton; Nathan Lawrentschuk
Journal:  Investig Clin Urol       Date:  2016-03-11

7.  Multidrug resistant epididymitis progressing to testicular infarct and orchiectomy.

Authors:  Nicholas J Farber; Rick C Slater; Jodi K Maranchie
Journal:  Case Rep Urol       Date:  2013-11-27

Review 8.  Prevalence, Risk Factors, and Clinical Relevance of Fluoroquinolone-Resistant Organisms in Rectal Cultures: Should We Target Antibiotic Prophylaxis Prior to Prostate Biopsy?

Authors:  J Van Besien; P Uvin; A M Van den Abeele; L Merckx
Journal:  Adv Urol       Date:  2016-03-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.